21.22
price up icon10.01%   1.93
after-market After Hours: 21.00 -0.22 -1.04%
loading
Anaptysbio Inc stock is traded at $21.22, with a volume of 1.39M. It is up +10.01% in the last 24 hours and up +42.32% over the past month. AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$19.29
Open:
$19.06
24h Volume:
1.39M
Relative Volume:
1.57
Market Cap:
$645.70M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-3.4901
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+45.54%
1M Performance:
+42.32%
6M Performance:
-38.76%
1Y Performance:
-4.80%
1-Day Range:
Value
$19.06
$21.47
1-Week Range:
Value
$12.21
$21.47
52-Week Range:
Value
$12.21
$41.31

Anaptysbio Inc Stock (ANAB) Company Profile

Name
Name
Anaptysbio Inc
Name
Phone
858-362-6295
Name
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Name
Employee
117
Name
Twitter
@anaptysbio
Name
Next Earnings Date
2024-11-08
Name
Latest SEC Filings
Name
ANAB's Discussions on Twitter

Compare ANAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ANAB
Anaptysbio Inc
21.22 645.70M 17.16M -163.62M -121.61M -6.08
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.00 117.92B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
673.60 73.64B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
639.41 38.85B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
256.45 33.20B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
119.83 28.73B 3.30B -501.07M 1.03B -2.1146

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-04-25 Initiated Wolfe Research Outperform
Dec-11-24 Downgrade H.C. Wainwright Buy → Neutral
Dec-02-24 Downgrade BTIG Research Buy → Neutral
Jul-22-24 Initiated H.C. Wainwright Buy
Jul-19-24 Upgrade JP Morgan Neutral → Overweight
Apr-16-24 Initiated Leerink Partners Outperform
Apr-11-24 Initiated Wells Fargo Overweight
Mar-12-24 Upgrade Wedbush Neutral → Outperform
Feb-26-24 Initiated BTIG Research Buy
Feb-21-24 Initiated Stifel Buy
Feb-16-24 Initiated Piper Sandler Overweight
May-22-23 Upgrade JP Morgan Underweight → Neutral
May-18-23 Initiated TD Cowen Outperform
Jan-06-23 Downgrade Raymond James Outperform → Mkt Perform
Nov-01-22 Upgrade Guggenheim Neutral → Buy
Sep-19-22 Resumed H.C. Wainwright Buy
Sep-13-22 Downgrade Truist Buy → Hold
Sep-01-22 Initiated Raymond James Outperform
Mar-22-22 Downgrade Guggenheim Buy → Neutral
Jun-22-21 Initiated H.C. Wainwright Buy
May-21-21 Initiated UBS Neutral
Mar-16-21 Upgrade Truist Hold → Buy
Mar-09-21 Downgrade Wedbush Outperform → Neutral
Mar-08-21 Downgrade JP Morgan Overweight → Underweight
Feb-11-21 Upgrade JP Morgan Underweight → Overweight
Oct-27-20 Upgrade Wedbush Neutral → Outperform
Oct-14-20 Upgrade Guggenheim Neutral → Buy
Nov-08-19 Downgrade JP Morgan Overweight → Underweight
Nov-08-19 Downgrade Jefferies Buy → Hold
Nov-08-19 Downgrade SunTrust Buy → Hold
Nov-08-19 Downgrade Wedbush Outperform → Neutral
Jun-21-19 Downgrade Credit Suisse Outperform → Neutral
Jun-21-19 Downgrade Stifel Buy → Hold
Dec-20-18 Initiated H.C. Wainwright Buy
Nov-21-18 Initiated JP Morgan Overweight
Jul-19-18 Initiated Credit Suisse Outperform
Apr-04-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-27-18 Reiterated Stifel Buy
Mar-06-18 Reiterated Stifel Buy
Feb-15-18 Reiterated SunTrust Buy
Jan-23-18 Reiterated Credit Suisse Outperform
Nov-15-17 Initiated SunTrust Buy
Nov-09-17 Initiated Jefferies Buy
Oct-11-17 Reiterated RBC Capital Mkts Outperform
Sep-15-17 Initiated RBC Capital Mkts Outperform
View All

Anaptysbio Inc Stock (ANAB) Latest News

pulisher
Feb 15, 2025

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

AnaptysBio price target raised to $22 from $19 at H.C. Wainwright - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

When the Price of (ANAB) Talks, People Listen - Stock Traders Daily

Feb 15, 2025
pulisher
Feb 15, 2025

Wells Fargo & Company Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $51.00 - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Wells Fargo & Company Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

AnaptysBio (NASDAQ:ANAB) Stock Price Up 16.5%Still a Buy? - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

What Analysts Were Expecting After AnaptysBio Inc (NASDAQ: ANAB) rose 19.44% - Stocks Register

Feb 14, 2025
pulisher
Feb 14, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected - Simply Wall St

Feb 14, 2025
pulisher
Feb 14, 2025

Positive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline - TipRanks

Feb 14, 2025
pulisher
Feb 13, 2025

AnaptysBio (NASDAQ:ANAB) Given Outperform Rating at Wedbush - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral By Investing.com - Investing.com Canada

Feb 13, 2025
pulisher
Feb 13, 2025

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data - Yahoo Finance

Feb 13, 2025
pulisher
Feb 13, 2025

H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

AnaptysBio (NASDAQ:ANAB) Receives "Outperform" Rating from Wedbush - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? - Yahoo Finance

Feb 13, 2025
pulisher
Feb 13, 2025

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - MSN

Feb 13, 2025
pulisher
Feb 12, 2025

Rosnilimab shows promise in rheumatoid arthritis trial By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 12, 2025

Rosnilimab shows promise in rheumatoid arthritis trial - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Vanda and AnaptysBio link for generalised pustular psoriasis therapy - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Anaptys stock surges on trial readout (update) (ANAB:NASDAQ) - Seeking Alpha

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio rockets on rosnilimab data - The Pharma Letter

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial - Yahoo Finance

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio climbs on arthritis drug trial data - TradingView

Feb 12, 2025
pulisher
Feb 12, 2025

Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial - Fierce Biotech

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio stock soars on positive RA trial results - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio Announces Promising Phase 2b RENOIR Trial Results - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

Anaptys Announces Rosnilimab Achieves Positive Results in Ra Phase 2B Trial and Highest Ever Reported Cdai Lda Response over 6 Months - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Anaptys surges as arthritis therapy succeeds in mid-stage trial - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Anaptys stock surges on trial readout (ANAB:NASDAQ) - Seeking Alpha

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio stock soars on positive RA trial results By Investing.com - Investing.com Australia

Feb 12, 2025
pulisher
Feb 12, 2025

Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial -February 12, 2025 at 07:44 am EST - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio announces Phase 2b RENOIR trial met primary endpoint - TipRanks

Feb 12, 2025
pulisher
Feb 12, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

AnaptysBio (ANAB) Stock Sees Strong Gains In Extended Session - Stocks Telegraph

Feb 12, 2025
pulisher
Feb 11, 2025

Anaptys to Announce Top-line Data from Phase 2b Trial of - GlobeNewswire

Feb 11, 2025
pulisher
Feb 11, 2025

AnaptysBio to Host Investor Call for Phase 2b RENOIR Trial Data of Rosnilimab in Rheumatoid Arthritis - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - Yahoo Finance

Feb 11, 2025
pulisher
Feb 10, 2025

Ratio Review: Analyzing AnaptysBio Inc (ANAB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Feb 10, 2025
pulisher
Feb 09, 2025

AnaptysBio (NASDAQ:ANAB) Upgraded by Wolfe Research to Strong-Buy Rating - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Wedbush Weighs in on AnaptysBio's Q1 Earnings (NASDAQ:ANAB) - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

AnaptysBio (NASDAQ:ANAB) Now Covered by Wolfe Research - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

SG Americas Securities LLC Buys 4,231 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World

Feb 08, 2025
pulisher
Feb 08, 2025

FY2029 Earnings Estimate for AnaptysBio Issued By Wedbush - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

AnaptysBio (NASDAQ:ANAB) Shares Gap UpStill a Buy? - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

Weekly Investment Analysts’ Ratings Updates for AnaptysBio (ANAB) - Defense World

Feb 07, 2025
pulisher
Feb 07, 2025

AnaptysBio's (ANAB) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Wedbush Reiterates "Outperform" Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Check Out AnaptysBio Inc (ANAB)’s Trade Data Rather Than the Analysts’ Views - SETE News

Feb 06, 2025

Anaptysbio Inc Stock (ANAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$79.31
price up icon 0.81%
$21.37
price down icon 2.06%
$370.58
price up icon 0.04%
$4.94
price up icon 7.39%
biotechnology ONC
$230.86
price up icon 2.38%
$119.83
price down icon 2.40%
Cap:     |  Volume (24h):